Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Parkinson's disease
Biotech
Former Inhibikase CEO launches new biotech for Parkinson's asset
ABLi Therapeutics licensed a drug discovery platform and Parkinson's candidate risvodetinib from Inhibikase.
Darren Incorvaia
May 12, 2025 12:44pm
Neurocrine hands back 2 CNS gene therapy programs to Voyager
May 7, 2025 7:30am
Verily nets $14.7M MJFF grant for personalized Parkinson's data
Apr 30, 2025 9:00am
Servier severing forces OPM to make 'drastic choices' to adapt
Apr 4, 2025 9:05am
Cerevance fails phase 2 trial in early, untreated Parkinson's
Apr 1, 2025 10:19am
Newronika nets CE mark for adaptive DBS in Parkinson's disease
Mar 26, 2025 10:36am
